Exploration of Clinical Breakpoint of Danofloxacin for Glaesserella parasuis in Plasma and in PELF

Background: In order to establish the clinical breakpoint (CBP) of danofloxacin against G. parasuis, three cutoff values, including epidemiological cutoff value (ECV), pharmacokinetic-pharmacodynamic (PK-PD) cutoff value (CO(PD)) and clinical cutoff value (CO(CL)), were obtained in the present study...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Zihui, Huang, Anxiong, Luo, Xun, Zhang, Peng, Huang, Lingli, Wang, Xu, Mi, Kun, Fang, Shiwei, Huang, Xiao, Li, Jun, Yuan, Zonghui, Hao, Haihong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8300709/
https://www.ncbi.nlm.nih.gov/pubmed/34356730
http://dx.doi.org/10.3390/antibiotics10070808

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8300709/
https://www.ncbi.nlm.nih.gov/pubmed/34356730
http://dx.doi.org/10.3390/antibiotics10070808

Ejemplares similares